Lanean...
Phase 0 Radiopharmaceutical–Agent Clinical Development
The evaluation of antibody-targeted or peptide-targeted radiopharmaceuticals as monotherapy or in oncological drug combinations requires programmatic collaboration within the National Cancer Institute (NCI) clinical trial enterprise. Phase 0 trials provide a flexible research platform for the study...
Gorde:
| Argitaratua izan da: | Front Oncol |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Frontiers Media S.A.
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7461940/ https://ncbi.nlm.nih.gov/pubmed/33014772 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.01310 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|